Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03109041 · ClinicalTrials.gov registry record · Phase 1
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
A Phase 1 study, sponsored by CivaTech Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03109041 is a Phase 1 study that has completed, run by CivaTech Oncology. The registered enrollment target is 2 participants.
The verdict
NCT03109041, a Phase 1 study, has completed, sponsored by CivaTech Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a Phase I evaluation to determine the usefulness of a new brachytherapy device that utilizes active components (Palladium-103) of standard devices in a novel configuration. This study may benefit resectable pancreatic cancer patients by reducing the radiation dose to adjacent critical structures, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.
Interventions
- DEVICE CivaSheet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-09-06 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03109041
The ClinicalTrials.gov registry entry for NCT03109041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CivaTech Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CivaSheet is the first listed.
NCT03109041 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03109041 about?
NCT03109041 is a clinical study titled "Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source". This is a Phase I evaluation to determine the usefulness of a new brachytherapy device that utilizes active components (Palladium-103) of standard devices in a novel configuration. This study may benefit resectable pancreatic cancer patients by reducing the radiation dose to adjacent critical struct...
What is the current status of trial NCT03109041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2017-09-06. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT03109041?
The interventions under investigation include: CivaSheet (DEVICE).
Who is sponsoring clinical trial NCT03109041?
This trial is sponsored by CivaTech Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.